Crossmark

Comment on “Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis”

Crossref DOI link: https://doi.org/10.1007/s00406-025-01958-5

Published Online: 2025-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wilkowska, Alina https://orcid.org/0000-0001-7258-6811
Cubała, Wiesław Jerzy
Funding

Funding for this research was provided by:

Gdański Uniwersytet Medyczny (01-10024/0006051/01/221/0/221/0/2024)
License Information

Text and Data Mining valid from 2025-01-22

Version of Record valid from 2025-01-22
More Information

Article History

Received: 13 November 2024

Accepted: 11 January 2025

First Online: 22 January 2025

Declarations

:

: Dr Alina Wilkowska has received research support from Angelini, Biogen, Eli Lilly and Company, Janssen- Cilag, Lundbeck, Polpharma, Sanofi and Valeant.Prof. Wiesław Jerzy Cubała has received the following research support. Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, BMS, Celon, Cephalon, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, Minerva, MSD, NIH, Novartis, Orion, Otsuka, Sanofi, Servier Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva, Advisory boards: Angelini, Celon (terminated), Douglas Pharmaceuticals, Janssen, MSD, Novartis, Sanofi.

Document is current

Any future updates will be listed below